News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novo Nordisk (NC) (NVO): Transaction in Own Shares


9/14/2009 11:52:55 AM

BAGSVAERD, DENMARK--(Marketwire - September 14, 2009) - Novo Nordisk A/S - Share repurchase programme

On 7 August 2009 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 2.4 billion in the period from 10 August 2009 to 18 December 2009.

Since the announcement as of 7 September 2009, the following transactions have been made under the programme:

                      Number of   Average purchase    Transaction
                        shares         price           value, DKK
                      --------------------------------------------
Accumulated, last
 announcement         1,521,000                       479,133,986
7 September 2009         55,000       316.5500         17,410,250
8 September 2009         66,000       319.0900         21,059,940
9 September 2009         75,000       318.5030         23,887,725
10 September 2009        75,000       322.2300         24,167,250
11 September 2009        75,000       326.5450         24,490,875
Accumulated under
 the programme        1,867,000                       590,150,026

With the transactions stated above, Novo Nordisk owns a total of 26,703,808 treasury shares, corresponding to 4.3% of the share capital. The total amount of shares in the company is 620,000,000 including treasury shares. Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 27,900 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.

Company Announcement No 54 / 2009

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Copyright © Hugin AS 2009. All rights reserved.


Further information:

Media:

Outside North America:
Mette Kruse Danielsen
Tel: (+45) 4442 3883
Email Contact

In North America:
Sean Clements
Tel: (+1) 609 514 8316
Email Contact

Investors:

Outside North America:
Mads Veggerby Lausten
Tel: (+45) 4443 7919
Email Contact

Kasper Roseeuw Poulsen
Tel: 4442 4471
Email Contact

In North America:
Hans Rommer
Tel: (+1) 609 919 7937
Email Contact


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES